

Jessica C Hassel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1233150/publications.pdf>

Version: 2024-02-01

171
papers

39,443
citations

46984

47
h-index

6643

156
g-index

177
all docs

177
docs citations

177
times ranked

36835
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 711-723.	13.9	13,065
2	Nivolumab in Previously Untreated Melanoma without BRAF Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	13.9	4,795
3	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 375-384.	5.1	2,353
4	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> , 2015, 350, 207-211.	6.0	2,275
5	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2012, 367, 107-114.	13.9	1,976
6	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2018, 4, 1721.	3.4	1,625
7	Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. <i>Nature</i> , 2016, 534, 396-401.	13.7	1,243
8	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855.	13.9	1,140
9	The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. <i>Cancer Discovery</i> , 2014, 4, 94-109.	7.7	782
10	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 190-209.	1.3	546
11	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. <i>JAMA Oncology</i> , 2016, 2, 234.	3.4	534
12	An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. <i>Nature</i> , 2020, 585, 107-112.	13.7	526
13	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 210-225.	1.3	490
14	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016, 22, 5487-5496.	3.2	480
15	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 2908-2918.	3.2	459
16	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 383-390.	0.8	431
17	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2021, 385, 1196-1206.	13.9	376
18	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. <i>Cancer Treatment Reviews</i> , 2016, 45, 7-18.	3.4	354

#	ARTICLE	IF	CITATIONS
19	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	3.4	295
20	IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. <i>Cell</i> , 2020, 182, 1252-1270.e34.	13.5	259
21	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. <i>Cancer Treatment Reviews</i> , 2017, 57, 36-49.	3.4	257
22	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3815-3822.	0.8	244
23	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	5.1	224
24	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet</i> , The, 2020, 395, 1558-1568.	6.3	188
25	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	5.1	183
26	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond. <i>Frontiers in Immunology</i> , 2018, 9, 1474.	2.2	174
27	Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B. <i>Clinical Cancer Research</i> , 2009, 15, 5208-5215.	3.2	168
28	Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. <i>European Journal of Cancer</i> , 2017, 75, 24-32.	1.3	162
29	Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 376-383.	3.3	160
30	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015, 25, 208-224.	5.7	143
31	Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. <i>ESMO Open</i> , 2019, 4, e000491.	2.0	140
32	Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 386-396.	3.3	130
33	Malignant Melanoma S3-Guideline –Diagnosis, Therapy and Follow-up of Melanoma–JDDG - <i>Journal of the German Society of Dermatology</i> , 2013, 11, 1-116.	0.4	122
34	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	0.8	119
35	Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. , 2019, 7, 299.		108
36	Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns—Results of a non-interventional study of the DeCOG. <i>European Journal of Cancer</i> , 2018, 96, 34-43.	1.3	97

#	ARTICLE	IF	CITATIONS
37	The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1289-1296.	3.3	90
38	Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 175-182.	2.0	90
39	Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations. <i>Journal of Clinical Oncology</i> , 2019, 37, 3142-3151.	0.8	83
40	Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. <i>Oncolmmunology</i> , 2016, 5, e1240859.	2.1	75
41	Tadalafil has biologic activity in human melanoma. Results of a pilot trial with <i>Tadalafil</i> in patients with metastatic Melanoma (TaMe). <i>Oncolmmunology</i> , 2017, 6, e1326440.	2.1	74
42	Comparison of molecular abnormalities in vulvar and vaginal melanomas. <i>Modern Pathology</i> , 2014, 27, 1386-1393.	2.9	70
43	Management of side effects of immune checkpoint blockade by anti-CTLA4 and anti-PD1 antibodies in metastatic melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 662-681.	0.4	63
44	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E/K mutant advanced or metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 109, 61-69.	1.3	63
45	UniCAR-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. <i>Scientific Reports</i> , 2020, 10, 2141.	1.6	62
46	STAT5 Contributes to Interferon Resistance of Melanoma Cells. <i>Current Biology</i> , 2005, 15, 1629-1639.	1.8	56
47	Immunotherapies for the Treatment of Uveal Melanoma—History and Future. <i>Cancers</i> , 2019, 11, 1048.	1.7	56
48	Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. , 2020, 8, e000333.		55
49	Melanoma brain metastases—Interdisciplinary management recommendations 2020. <i>Cancer Treatment Reviews</i> , 2020, 89, 102083.	3.4	52
50	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel) Tj ETQq0 0 0 rgBT /Overlock 10 T		52
51	Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide ¹³¹ I-BA52. <i>Journal of Nuclear Medicine</i> , 2014, 55, 9-14.	2.8	48
52	Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma. <i>Melanoma Research</i> , 2017, 27, 321-325.	0.6	46
53	The Outcome of <i>Ex Vivo</i> TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic <i>In Vitro</i> Growth Capacity between T-Cell Clones. <i>Clinical Cancer Research</i> , 2020, 26, 4289-4301.	3.2	46
54	Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 297-303.	2.0	45

#	ARTICLE	IF	CITATIONS
55	Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. <i>European Journal of Cancer</i> , 2019, 110, 11-20.	1.3	44
56	Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. <i>European Journal of Cancer</i> , 2020, 138, 125-132.	1.3	44
57	Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy. <i>European Journal of Cancer</i> , 2018, 104, 239-242.	1.3	43
58	¹⁸ F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. <i>Melanoma Research</i> , 2019, 29, 178-186.	0.6	43
59	Clinical significance of signs of autoimmune colitis in ¹⁸ F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. <i>Immunotherapy</i> , 2019, 11, 667-676.	1.0	41
60	Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. , 2020, 8, e000897.		40
61	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 147, 170-181.	1.3	40
62	PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma. <i>Acta Dermato-Venereologica</i> , 2017, 97, 395-396.	0.6	39
63	Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2257-2267.	3.2	39
64	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	5.1	37
65	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 765-772.	2.0	35
66	STAT5 contributes to antiapoptosis in melanoma. <i>Melanoma Research</i> , 2008, 18, 378-385.	0.6	34
67	Chemovirotherapy of Malignant Melanoma with a Targeted and Armed Oncolytic Measles Virus. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1034-1042.	0.3	34
68	Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. <i>British Journal of Cancer</i> , 2018, 118, 785-792.	2.9	34
69	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. , 2021, 9, e003066.		34
70	Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients. <i>Oncolimmunology</i> , 2021, 10, 1926762.	2.1	32
71	Serological Immunomarkers in Cutaneous T Cell Lymphoma. <i>Dermatology</i> , 2004, 209, 296-300.	0.9	30
72	Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab. <i>EJNMMI Research</i> , 2016, 6, 61.	1.1	29

#	ARTICLE	IF	CITATIONS
73	Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases. <i>Journal of Immunotherapy</i> , 2017, 40, 282-285.	1.2	28
74	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	1.3	28
75	Sensitivity of different MRI sequences in the early detection of melanoma brain metastases. <i>PLoS ONE</i> , 2018, 13, e0193946.	1.1	27
76	Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. <i>European Journal of Cancer</i> , 2014, 50, 406-410.	1.3	26
77	Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?. <i>Cancer Medicine</i> , 2017, 6, 1581-1586.	1.3	26
78	Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression. <i>American Journal of Hematology</i> , 2020, 95, 1158-1169.	2.0	25
79	Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an update. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 582-609.	0.4	24
80	Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. <i>Diagnostics</i> , 2018, 8, 76.	1.3	23
81	Predicting tooth color from facial features and gender: Results from a white elderly cohort. <i>Journal of Prosthetic Dentistry</i> , 2008, 99, 101-106.	1.1	22
82	Psychosomatic or allergic symptoms? High levels for somatization in patients with drug intolerance. <i>Journal of Dermatology</i> , 2011, 38, 959-965.	0.6	22
83	Rituximab as a therapeutic option for patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 917-924.	2.0	22
84	Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1261-1270.	2.0	22
85	Phenol Chemical Matricectomy Is Less Painful, with Shorter Recovery Times but Higher Recurrence Rates, Than Surgical Matricectomy: A Patient's View. <i>Dermatologic Surgery</i> , 2010, 36, 1294-1299.	0.4	21
86	Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. <i>Pathology</i> , 2018, 50, 703-710.	0.3	21
87	Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma. , 2022, 10, e003198.		21
88	Ipilimumab plus nivolumab for advanced melanoma. <i>Lancet Oncology</i> , The, 2016, 17, 1471-1472.	5.1	20
89	Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1823-1832.	2.0	19
90	Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study. <i>European Journal of Cancer</i> , 2021, 152, 41-48.	1.3	18

#	ARTICLE	IF	CITATIONS
91	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. <i>Cancers</i> , 2021, 13, 3359.	1.7	18
92	Promising Results from a Pilot Study on Compression Treatment of Ear Keloids. <i>Journal of Cutaneous Medicine and Surgery</i> , 2011, 15, 130-136.	0.6	17
93	Vemurafenib and ipilimumab: A promising combination? Results of a case series. <i>Oncolmmunology</i> , 2016, 5, e1101207.	2.1	17
94	Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1932-1943.	3.3	17
95	Histogram analysis of iodine maps from dual energy computed tomography for monitoring targeted therapy of melanoma patients. <i>Future Oncology</i> , 2015, 11, 591-606.	1.1	16
96	Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma. <i>Cancer Medicine</i> , 2018, 7, 95-104.	1.3	16
97	Adenoviruses Using the Cancer Marker EphA2 as a Receptor In Vitro and In Vivo by Genetic Ligand Insertion into Different Capsid Scaffolds. <i>PLoS ONE</i> , 2014, 9, e95723.	1.1	15
98	Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 1080-1081.	1.0	15
99	Prophylaxis and Management of Skin Toxicities. <i>Breast Care</i> , 2019, 14, 72-77.	0.8	15
100	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021, 148, 61-75.	1.3	15
101	Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. <i>Cancers</i> , 2021, 13, 2319.	1.7	15
102	Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study. <i>EJNMMI Research</i> , 2021, 11, 89.	1.1	15
103	Treatment of Ear Keloids by Compression, Using a Modified Oyster-Splint Technique. <i>Dermatologic Surgery</i> , 2007, 33, 208-212.	0.4	14
104	Primary melanoma of the prostate: case report and review of the literature. <i>BMC Urology</i> , 2015, 15, 68.	0.6	14
105	Immunotherapy of Melanoma. <i>Oncology Research and Treatment</i> , 2016, 39, 369-376.	0.8	14
106	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA8509-LBA8509.	0.8	14
107	Raster-scanned intensity-controlled carbon ion therapy for mucosal melanoma of the paranasal sinus. <i>Head and Neck</i> , 2016, 38, E1445-51.	0.9	13
108	Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment. <i>Annals of Oncology</i> , 2016, 27, 1353-1354.	0.6	13

#	ARTICLE	IF	CITATIONS
109	Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. <i>European Journal of Cancer</i> , 2021, 152, 139-154.	1.3	13
110	Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA). <i>Oncolimmunology</i> , 2022, 11, 2066609.	2.1	13
111	Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors. <i>Cancers</i> , 2021, 13, 1019.	1.7	12
112	Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. <i>European Journal of Cancer</i> , 2021, 149, 37-48.	1.3	12
113	Which melanoma patient carries a BRAF-mutation? A comparison of predictive models. <i>Oncotarget</i> , 2016, 7, 36130-36137.	0.8	12
114	Lecithin retinol acyltransferase as a potential prognostic marker for malignant melanoma. <i>Experimental Dermatology</i> , 2013, 22, 757-759.	1.4	11
115	Susceptibility-weighted imaging in malignant melanoma brain metastasis. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 1251-1259.	1.9	11
116	Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 1438.	1.0	11
117	Stereotactic Radiosurgery With Concurrent Immunotherapy in Melanoma Brain Metastases Is Feasible and Effective. <i>Frontiers in Oncology</i> , 2020, 10, 592796.	1.3	10
118	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatoooncology Group. <i>European Journal of Cancer</i> , 2021, 149, 1-10.	1.3	10
119	Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma. <i>Cancer Research</i> , 2021, 81, CT002-CT002.	0.4	10
120	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 765608.	1.3	10
121	MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study. <i>European Journal of Cancer</i> , 2022, 166, 24-32.	1.3	10
122	Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2051-2056.	2.0	10
123	Liquid Biopsy: Value for Melanoma Therapy?. <i>Oncology Research and Treatment</i> , 2017, 40, 430-434.	0.8	9
124	The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice. <i>Journal of Investigative Dermatology</i> , 2017, 137, 261-264.	0.3	9
125	Positron Emission Tomography in Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2897.	1.7	9
126	STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon- γ . <i>Melanoma Research</i> , 2018, 28, 204-210.	0.6	8

#	ARTICLE	IF	CITATIONS
127	Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. <i>Cancers</i> , 2021, 13, 2616.	1.7	8
128	TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma. <i>Cancers</i> , 2022, 14, 1215.	1.7	8
129	Targeted Therapy for Melanomas Without BRAF V600 Mutations. <i>Current Treatment Options in Oncology</i> , 2022, 23, 831-842.	1.3	8
130	Varicella-Like Cutaneous Toxoplasmosis in a Patient with Aplastic Anemia. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1341-1344.	1.8	7
131	Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells. <i>Life</i> , 2021, 11, 269.	1.1	7
132	Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma. <i>Life</i> , 2021, 11, 1318.	1.1	7
133	Genetic characterization of advanced conjunctival melanoma and response to systemic treatment. <i>European Journal of Cancer</i> , 2022, 166, 60-72.	1.3	7
134	Therapy Response Assessment in Metastatic Melanoma Patients Treated with a BRAF Inhibitor. <i>Academic Radiology</i> , 2013, 20, 423-429.	1.3	6
135	RAS Mutations in Benign Epithelial Tumors Associated with BRAF Inhibitor Treatment of Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 636-639.	0.3	6
136	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity. <i>Cancers</i> , 2022, 14, 518.	1.7	6
137	¹⁸ F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab. <i>Clinical Nuclear Medicine</i> , 2016, 41, 156-158.	0.7	5
138	5-year results for pembrolizumab treatment of advanced melanoma. <i>Lancet Oncology</i> , The, 2019, 20, 1187-1189.	5.1	5
139	Human innate immune cell crosstalk induces melanoma cell senescence. <i>Oncolmmunology</i> , 2020, 9, 1808424.	2.1	5
140	In vivo visualization of mesoscopic anatomy of healthy and pathological lymph nodes using 7T MRI: A feasibility study. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 1405-1412.	1.9	4
141	Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. <i>Cancers</i> , 2022, 14, 1804.	1.7	4
142	Axillary accessory breast tissue – case report and review of literature. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 499-500.	0.4	3
143	Limitations of Ber-EP4 for distinction of Bowen disease from basal cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 367-371.	0.7	3
144	Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients. <i>Cancers</i> , 2020, 12, 3004.	1.7	3

#	ARTICLE	IF	CITATIONS
145	546â€¦Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM). , 2021, 9, A576-A576.		3
146	Two cases of intralymphatic histiocytosis following hip replacement. JDDG - Journal of the German Society of Dermatology, 2015, 13, 700-702.	0.4	2
147	Health-related quality of life trajectory of treatment-naïve patients with Merkel cell carcinoma receiving avelumab. Future Oncology, 2020, 16, 2089-2099.	1.1	2
148	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). Journal of Cancer Research and Clinical Oncology, 2021, 147, 1763-1771.	1.2	2
149	Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study. Frontiers in Oncology, 2021, 11, 672172.	1.3	2
150	Durable complete remission of leptomeningeal melanoma by intrathecal methotrexate maintained with systemic ipilimumab. Immunotherapy, 2021, 13, 1079-1083.	1.0	2
151	549â€¦An RNA-lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a Phase I trial in cutaneous melanoma patients with no evidence of disease at trial inclusion. , 2021, 9, A579-A579.		2
152	538â€¦Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp. , 2021, 9, A568-A568.		2
153	Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy. Strahlentherapie Und Onkologie, 2022, 198, 884-891.	1.0	2
154	Necrolytic Migratory Erythema in a Patient with Neuroendocrine Carcinoma. Internal Medicine, 2013, 52, 151-152.	0.3	1
155	Solitary, Well-Circumscribed, Depressed Palmar Lesion. American Journal of Dermatopathology, 2015, 37, 166.	0.3	1
156	Four cases of erysipelas-like inflammation in patients with metastatic melanoma treated with checkpoint inhibitors. JDDG - Journal of the German Society of Dermatology, 2021, 19, 598-602.	0.4	1
157	Generalized perforating granuloma annulare: a case report. JDDG - Journal of the German Society of Dermatology, 2021, 19, 585-587.	0.4	1
158	Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial. Trials, 2021, 22, 294.	0.7	1
159	Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib. Hellenic Journal of Nuclear Medicine, 2017, 20, 251-253.	0.2	1
160	Fractal and Multifractal Analysis of PET-CT Images for Therapy Assessment of Metastatic Melanoma Patients under PD-1 Inhibitors: A Feasibility Study. Cancers, 2021, 13, 5170.	1.7	1
161	Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma. British Journal of Cancer, 2021, , .	2.9	1
162	Tebentafusp for the treatment of metastatic uveal melanoma. Future Oncology, 2022, 18, 1303-1311.	1.1	1

#	ARTICLE	IF	CITATIONS
163	Solitary, Well-Circumscribed Depressed Palmar Lesion. American Journal of Dermatopathology, 2015, 37, 156.	0.3	0
164	Exanthematous cutaneous spread of metastatic urothelial carcinoma in a 69-year-old man. JDDG - Journal of the German Society of Dermatology, 2016, 14, 1300-1302.	0.4	0
165	Bone Formation in Cutaneous Nodules on the Leg: A Quiz. Acta Dermato-Venereologica, 2017, 97, 1263-1264.	0.6	0
166	Cerebral metastases of a dermatofibrosarcoma protuberans. JDDG - Journal of the German Society of Dermatology, 2020, 18, 143-145.	0.4	0
167	Pleomorphic dermal sarcoma with cerebral metastasis. JDDG - Journal of the German Society of Dermatology, 2020, 18, 886-888.	0.4	0
168	Multiple alopecic patches in the hairy scalp area of a 28-year-old female patient. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1222-1224.	0.4	0
169	Ipilimumab use in a named-patient program in metastatic melanoma: Experiences in 185 German patients.. Journal of Clinical Oncology, 2012, 30, e19031-e19031.	0.8	0
170	Compression Treatment of Ear Keloids by a Modified Oyster Splint Technique. , 2013, , 499-505.		0
171	Skin Care During and After Radiotherapy and Anticancer Treatment. , 2020, , 1-16.		0